{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:36:21Z","timestamp":1769092581456,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.clml.2014.07.015","type":"journal-article","created":{"date-parts":[[2014,8,2]],"date-time":"2014-08-02T18:03:12Z","timestamp":1407002592000},"page":"59-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board"],"prefix":"10.1016","volume":"15","author":[{"given":"John","family":"Kuruvilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Christofides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Komolova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Connors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.07.015_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","author":"International Lymphoma Study Group","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib3","first-page":"213","article-title":"Follicular lymphoma: expanding therapeutic options","volume":"19","author":"Ganti","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2014.07.015_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-12-210","article-title":"Has the time to come leave the \u201cwatch-and-wait\u201d strategy in newly diagnosed asymptomatic follicular lymphoma patients?","volume":"12","author":"Rueda","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2014.07.015_bib5","first-page":"120","article-title":"Classification of non-Hodgkin lymphoma in six geographic regions around the world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project [abstract]","volume":"31","author":"Perry","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib6","unstructured":"Canadian Cancer Society. Canadian Cancer Society\u2019s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics. Canadian Cancer Society. Available at: http:\/\/www.cancer.ca\/\u223c\/media\/cancer.ca\/CW\/cancer%20information\/cancer%20101\/Canadian%20cancer%20statistics\/canadian-cancer-statistics-2013-EN.pdf. Accessed March 18,\u00a02014."},{"key":"10.1016\/j.clml.2014.07.015_bib7","unstructured":"Canadian Cancer Society. Canadian Cancer Statistics. Available at: http:\/\/www.cancer.ca\/en\/cancer-information\/cancer-101\/canadian-cancer-statistics-publication\/?region=on. Accessed March 18,\u00a02014."},{"key":"10.1016\/j.clml.2014.07.015_bib8","first-page":"368","article-title":"Staging non-Hodgkin lymphoma","volume":"55","author":"Armitage","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2014.07.015_bib9","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal-C\u00e9ligny","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation.V2009.1.523.0010523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.07.015_bib11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib12","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/PPO.0b013e31826aed6d","article-title":"What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?","volume":"18","author":"Kenkre","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2014.07.015_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/asheducation-2006.1.303","article-title":"Controversies in follicular lymphoma: \u201cwho, what, when, where, and why?\u201d (not necessarily in that order!)","author":"Czuczman","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.07.015_bib15","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.6004\/jnccn.2013.0037","article-title":"Non-Hodgkin's lymphomas, version 1.2013","volume":"11","author":"Zelenetz","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"suppl 6","key":"10.1016\/j.clml.2014.07.015_bib17","doi-asserted-by":"crossref","first-page":"vi59","DOI":"10.1093\/annonc\/mdr388","article-title":"ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Dreyling","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","article-title":"Guidelines on the investigation and management of follicular lymphoma","volume":"156","author":"McNamara","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.07.015_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.23372","article-title":"SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma","volume":"88","author":"Zinzani","year":"2013","journal-title":"Am J Hematol"},{"issue":"suppl 3","key":"10.1016\/j.clml.2014.07.015_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2011.629897","article-title":"Clinical practice guidelines for first-line\/after-relapse treatment of patients with follicular lymphoma","volume":"52","author":"L\u00f3pez-Guillermo","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.07.015_bib21","unstructured":"Alberta Health Services. Alberta Health Services. Lymphoma. Clinical Practice Guideline LYHE-002 (version 8). Available at: http:\/\/www.albertahealthservices.ca\/hp\/if-hp-cancer-guide-lyhe002-lymphoma.pdf. Accessed August 9,\u00a02014."},{"key":"10.1016\/j.clml.2014.07.015_bib22","unstructured":"British Colombia Cancer Agency. Cancer management guidelines. Malignant lymphoma. British Colombia Cancer Agency, 2013. Available at: http:\/\/www.bccancer.bc.ca\/HPI\/CancerManagementGuidelines\/Lymphoma\/HD\/default.htm. Accessed August 9,\u00a02014."},{"key":"10.1016\/j.clml.2014.07.015_bib23","unstructured":"Sabio R. Canadian guideline needed for the treatment of follicular lymphoma (Available at: http:\/\/www.newevidence.com\/oncology\/entries\/Canadian_Guideline_Needed_for_the_Treatment\/). Accessed: June 23, 2014."},{"key":"10.1016\/j.clml.2014.07.015_bib24","unstructured":"National Comprehensive Cancer Network. NCCN categories of evidence and consensus. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/categories_of_consensus.asp. Accessed: March 18,\u00a02014."},{"key":"10.1016\/j.clml.2014.07.015_bib25","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.25149","article-title":"Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis","volume":"116","author":"Pugh","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.015_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-6-45","article-title":"Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?","volume":"6","author":"Michallet","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib27","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.015_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2014.07.015_bib29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/PL00002370","article-title":"Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy","volume":"177","author":"Frank","year":"2001","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clml.2014.07.015_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0360-3016(03)00592-3","article-title":"Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study","volume":"57","author":"Ha","year":"2003","journal-title":"Int J\u00a0Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2014.07.015_bib31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J\u00a0Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2014.07.015_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1748-717X-7-103","article-title":"Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation","volume":"7","author":"Guckenberger","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00066-011-0057-0","article-title":"Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients","volume":"188","author":"Fakhrian","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clml.2014.07.015_bib34","doi-asserted-by":"crossref","first-page":"e65156","DOI":"10.1371\/journal.pone.0065156","article-title":"Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone","volume":"8","author":"Ahmed","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2014.07.015_bib35","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib37","author":"Hoppe"},{"key":"10.1016\/j.clml.2014.07.015_bib38","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1200\/jco.2004.22.90140.6521","article-title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone [abstract]","volume":"22","author":"Petersen","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib39","first-page":"iv90","article-title":"Follicular lymphoma: curability by radiotherapy in limited stage nodal disease? Updated results of a randomized trial [abstract]","volume":"22","author":"Engelhard","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib40","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib41","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait\u00a0policy versus immediate systemic treatment for asymptomatic advanced-stage\u00a0non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.07.015_bib43","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib44","first-page":"11","article-title":"The\u00a0treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2014.07.015_bib45","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood.V118.21.LBA-6.bld0076_P3_LBA-6","article-title":"Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase iii study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]","volume":"118","author":"Kahl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib47","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib48","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib49","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.07.015_bib50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib51","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib52","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib53","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib54","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib55","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for\u00a0the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib56","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.07.015_bib57","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib58","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib59","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in\u00a0patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"issue":"suppl 2","key":"10.1016\/j.clml.2014.07.015_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.2009-S2-17","article-title":"Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence","volume":"14","author":"Morschhauser","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2014.07.015_bib62","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","volume":"31","author":"Vitolo","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.07.015_bib64","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib65","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib66","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib67","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib68","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.015_bib69","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.015_bib70","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood.V122.21.551.551","article-title":"Prolonged survival of poor risk follicular lymphoma patients following primary treatment with rituximab-supplemented CHOP or HDS with autograft: long-term results of the multicenter randomized GITMO\/FIL trial [abstract]","volume":"122","author":"Tarella","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014003103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014003103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:29Z","timestamp":1761870329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014003103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S2152265014003103"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.07.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}